EGFR and non-small cell lung carcinoma: For epidermal growth factor receptor (EGFR)-mutated NSCLC, the third-generation osimertinib superseded earlier agents after the FLAURA trial showed objective response rates > 70%, a median progression-free survival of 18.9 months, and a 52% reduction in the risk of CNS progression [13].